Document is current
Any future updates will be listed below
-
Authors
Kasahara, Kazuyuki https://orcid.org/0000-0003-3303-7216
Kerby, Robert L.
Aquino-Martinez, Ruben
Evered, Abigail H.
Cross, Tzu-Wen L.
Everhart, Jessica
Ulland, Tyler K.
Kay, Colin D. https://orcid.org/0000-0001-7290-4496
Bolling, Bradley W.
Bäckhed, Fredrik
Rey, Federico E. https://orcid.org/0000-0002-0239-7780
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (HL144651, HL148577, HL007936)
Fondation Leducq (17CVD01, 17CVD01)
- License Information
-
More Information
Article History
Received: 31 December 2022
Accepted: 27 November 2024
First Online: 10 January 2025
Competing interests
: F.B. is co-founder and shareholder of Roxbiosens Inc and Implexion Pharma AB, receives research funding from Biogaia AB, and is a member of the scientific advisory board of Bactolife A/S.
